PipelineReview.com - TCR T-Cells and Antibodies

Show Cart

TCR T-Cells and Antibodies

Results 11 - 16 of 16

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

(Discount: 33.33%)

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

(Discount: 20.00%)

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

Dec 2012 Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

Start
Prev
1
2
Next
End

Shopping cart

Cart empty

Latest report

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Featured Products

Report Package: Bispecific Antibodies

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Latest Target Pipeline

CD38-Targeted Antibody & Cell Therapy

Shopping cart

Cart empty

Latest report

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Featured Products

Report Package: Bispecific Antibodies

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Latest Target Pipeline

CD38-Targeted Antibody & Cell Therapy

La Merie Biologics

FREE Weekly News Bulletin

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing